Incyte is a high-quality, fast-growing biotech with a wide moat and a strong earnings beat streak, but the stock sits 0.8% below the $116.59 analyst target with earnings 5 days away, leaving little near-term upside.
Thesis pillars
- High Quality Wide Moat→Stable
- Strong Revenue Growth→Stable
- Earnings Beat Streak→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026, based on the 10-K filed Feb 10, 2026
Incyte Corporation (INCY) Stock Analysis
Healthcare · Biotechnology
Wait for pullback to $109.28. Price sits above the model's entry target of $109.28; the risk/reward becomes favorable on a pullback. Key risk: Analyst target reached - limited upside remaining.
Incyte is a global biopharmaceutical company commercializing seven approved products across Hematology, Oncology, and Inflammation/Autoimmunity, led by JAKAFI (ruxolitinib), whose U.S. composition-of-matter and use patents expire in mid and late 2028. Revenue flows from U.S.... Read more
Wait for pullback to $109.28. Price sits above the model's entry target of $109.28; the risk/reward becomes favorable on a pullback. Key risk: Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Earnings today. Wait until post-earnings. Score 7.2/10, high confidence.
Passes 5/8 gates (positive momentum, clean insider activity, news boost earnings 0.80, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 0d<=7d. Suitability: speculative.
About Incyte Corporation
About Incyte Corporation
JAKAFI (ruxolitinib) composition-of-matter and use patents—Incyte Corporation's primary commercial asset across myelofibrosis, polycythemia vera, and graft-versus-host disease—expire in mid and late 2028, respectively. Incyte markets seven approved products across Hematology, Oncology, and Inflammation & Autoimmunity from its Wilmington, Delaware headquarters, with commercial and development operations in Europe (Morges, Switzerland), Japan (Tokyo), and Canada (Montreal). NIKTIMVO (axatilimab-csfr) commenced U.S. commercial launch in January 2025 following August 2024 FDA approval for third-line chronic GVHD.
Revenue flows from multiple streams. JAKAFI is marketed through Incyte's own specialty sales force in the United States and distributed through specialty pharmacy providers and wholesalers; ruxolitinib is commercialized outside the United States as JAKAVI under a collaboration with Novartis, which holds exclusive non-U.S. hematologic and oncologic rights and pays Incyte sales milestones and royalties. Eli Lilly pays royalties on OLUMIANT (baricitinib) sales across rheumatoid arthritis, atopic dermatitis, alopecia areata, and COVID-19. OPZELURA (ruxolitinib cream), approved by the FDA for atopic dermatitis in September 2021 and vitiligo in July 2022, distributes through the same specialty channel. ZYNYZ (retifanlimab-dlwr) received FDA approval for squamous cell carcinoma of the anal canal in May 2025 and a positive European CHMP opinion in January 2026. Ruxolitinib XR targets a mid-2026 regulatory decision after a March 2023 Complete Response Letter was addressed via a completed bioequivalence study.
Show full overview
Distribution concentration adds a layer of commercial risk: a limited number of specialty pharmacies and wholesalers represent a significant portion of revenues from JAKAFI and most other products, with no alternative channel disclosed. Ruxolitinib phosphate qualifies for the CMS Small Biotech Exception under the Inflation Reduction Act, delaying Medicare price negotiation—though the exception does not block post-expiry generic entry. If ruxolitinib XR misses its mid-2026 regulatory decision, the JAKAFI franchise would enter generic competition without a formulation bridge. The frontMIND Phase 3 tafasitamab/lenalidomide DLBCL trial met its primary progression-free survival endpoint in January 2026, and a supplemental BLA filing is planned for the first half of 2026, providing incremental revenue diversification before the JAKAFI patent cliff.
See also: Healthcare · Biotechnology
From Incyte Corporation's most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-10-29Recent Developments — Incyte Corporation
Latest news
- NEWS INCY or TECH: Which Is the Better Value Stock Right Now? - Yahoo Finance — Yahoo Finance neutral
- NEWS INCY or TECH: Which Is the Better Value Stock Right Now? - finance.yahoo.com — finance.yahoo.com neutral
- NEWS Learn Why The Bull Case For Incyte (INCY) Could Change Following Rare Disease Drug Approval - Simply Wall Street — Simply Wall Street positive
- NEWS Incyte Shares Retreat After Best Day In A Year Despite Opzelura EU Nod - TradingView — TradingView neutral
- NEWS Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results - Benzinga — Benzinga positive
Generated 2026-10-29T11:53:51Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductJAKAFI10-K Item 1A: 'We depend heavily on JAKAFI/JAKAVI (ruxolitinib), and if we are not able to maintain revenues from JAKAFI/JAKAVI or those revenues decrease, our business may be materially harmed.'
- MEDIUMCustomerlimited number of specialty pharmacies and wholesalers10-K Item 1A: 'A limited number of specialty pharmacies and wholesalers represent a significant portion of revenues from JAKAFI and most of our other products'
Material Events(8-K, last 90d)
- 2026-03-30Item 5.02LOWSusanne Schaffert resigned from Incyte's Board effective April 15, 2026. Board member since 2022. No disagreement with operations, policies, or practices cited. No successor named.SEC filing →
- 2026-03-26Item 5.02LOWIncyte announced title changes effective March 25, 2026: Pablo Cagnoni named President and Global Head of R&D (replacing Meury as President; Meury remains CEO); Steven Stein named EVP/CMO; Mohamed Issa named EVP and Head of U.S. Commercial. No compensation changes.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 ceiling hits
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $109.28. Price sits above the model's entry target of $109.28; the risk/reward becomes favorable on a pullback. Key risk: Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Earnings today. Wait until post-earnings. Analyst target $116.59 reached (−0.2%), stop $104.55 (−11.8%), A.R:R -0.0:1. Score 7.2/10, high confidence.
Analyst target $116.59 reached (−0.2% from $116.87); no take-profit level is published. Analyst target $116.59 reached (−0.2%), stop $104.55 (−11.8%), A.R:R -0.0:1. Stop-loss: $104.55.
Analyst target reached - limited upside remaining.
Incyte Corporation trades at a P/E of 14.9 (forward 13.4). TrendMatrix value score: 6.6/10. Verdict: Buy (Wait for Entry).
35 analysts cover INCY with a consensus score of 3.7/5. Average price target: $130.
What does Incyte Corporation do?Incyte is a global biopharmaceutical company commercializing seven approved products across Hematology, Oncology, and...
Incyte is a global biopharmaceutical company commercializing seven approved products across Hematology, Oncology, and Inflammation/Autoimmunity, led by JAKAFI (ruxolitinib), whose U.S. composition-of-matter and use patents expire in mid and late 2028. Revenue flows from U.S. specialty pharmacy distribution of JAKAFI, OPZELURA, and ZYNYZ and royalties from Novartis on JAKAVI and Eli Lilly on OLUMIANT.